Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
Pedelco
Pedelco Jan. 14 at 8:42 PM
$CLRB super bullish
0 · Reply
revuelto
revuelto Jan. 14 at 7:22 PM
$CLRB after hours news would be welcome 😀👍
1 · Reply
higgggghhhher
higgggghhhher Jan. 14 at 6:06 PM
$CLRB CSR is going to be for the whole trial of clr 131..All the Indications. Ended late December
0 · Reply
Glopolon
Glopolon Jan. 14 at 3:30 PM
$CLRB trades as a low float. Wide bid/ask spreads, large price moves are easy.
0 · Reply
revuelto
revuelto Jan. 14 at 3:28 PM
$CLRB price action isn’t concerning…I am always sus with nano and micro caps with limited runway…. this is heading much higher✌️
0 · Reply
EvenBetter99
EvenBetter99 Jan. 14 at 6:36 AM
$CLRB Selling the company for USD 1 Billion+ would be ok. But not for fe USD 300 Million. It is not a really good option imho. 🚀🚀🚀🚀🚀
0 · Reply
Glopolon
Glopolon Jan. 14 at 4:50 AM
$CLRB FDA has a long history of incompetence
0 · Reply
bananastand1203
bananastand1203 Jan. 14 at 1:46 AM
$CLRB Can someone explain to me why the FDA is requiring a confirmatory study for WM but not EMA? Usually FDA is more lenient than EMA
1 · Reply
Zergg
Zergg Jan. 14 at 12:22 AM
$CLRB really hoping for a partnership asap. Either way i’m stacking as much as I can
0 · Reply
Slab6
Slab6 Jan. 14 at 12:09 AM
$CLRB go back to $2.50 so I can buy more lol
0 · Reply
Latest News on CLRB
Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 9 months ago

Cellectar Announces Plan to Explore Strategic Alternatives


Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 10 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript


Pedelco
Pedelco Jan. 14 at 8:42 PM
$CLRB super bullish
0 · Reply
revuelto
revuelto Jan. 14 at 7:22 PM
$CLRB after hours news would be welcome 😀👍
1 · Reply
higgggghhhher
higgggghhhher Jan. 14 at 6:06 PM
$CLRB CSR is going to be for the whole trial of clr 131..All the Indications. Ended late December
0 · Reply
Glopolon
Glopolon Jan. 14 at 3:30 PM
$CLRB trades as a low float. Wide bid/ask spreads, large price moves are easy.
0 · Reply
revuelto
revuelto Jan. 14 at 3:28 PM
$CLRB price action isn’t concerning…I am always sus with nano and micro caps with limited runway…. this is heading much higher✌️
0 · Reply
EvenBetter99
EvenBetter99 Jan. 14 at 6:36 AM
$CLRB Selling the company for USD 1 Billion+ would be ok. But not for fe USD 300 Million. It is not a really good option imho. 🚀🚀🚀🚀🚀
0 · Reply
Glopolon
Glopolon Jan. 14 at 4:50 AM
$CLRB FDA has a long history of incompetence
0 · Reply
bananastand1203
bananastand1203 Jan. 14 at 1:46 AM
$CLRB Can someone explain to me why the FDA is requiring a confirmatory study for WM but not EMA? Usually FDA is more lenient than EMA
1 · Reply
Zergg
Zergg Jan. 14 at 12:22 AM
$CLRB really hoping for a partnership asap. Either way i’m stacking as much as I can
0 · Reply
Slab6
Slab6 Jan. 14 at 12:09 AM
$CLRB go back to $2.50 so I can buy more lol
0 · Reply
Diegovj
Diegovj Jan. 14 at 12:03 AM
$CLRB “Here, ex-US, you can see we received the CMA eligibility. We were submitting in and around the early part of the third quarter, and we fully expect an approval, and then the subsequent commercialization there in early 2027. In the US, again, this is something that we look at and would initiate post a partnership. Those discussions are currently ongoing.”
0 · Reply
revuelto
revuelto Jan. 13 at 11:26 PM
$CLRB going by Caruso’s tone it doesn’t sound like an acquisition is in the works…just announce a partnership on strong terms already, Caruso…make it happen!
0 · Reply
Zergg
Zergg Jan. 13 at 11:11 PM
$CLRB to infinity and beyond!
0 · Reply
Diegovj
Diegovj Jan. 13 at 10:26 PM
$CLRB From today’s presentation: • Company confirmed they are preparing the full Clinical Study Report (CSR) for WM to support EU CMA • EMA readiness meeting planned in 1Q, with CMA submission targeted for 3Q
1 · Reply
EvenBetter99
EvenBetter99 Jan. 13 at 10:25 PM
$CLRB soon WSB coming and soon a dramatic upside movements 🚀🚀🚀 outstanding data + very clear path + very very low marketcap + pipeline
0 · Reply
Glopolon
Glopolon Jan. 13 at 10:14 PM
$CLRB Phase I breast cancer data Q1.
0 · Reply
Investeermeermeneer
Investeermeermeneer Jan. 13 at 10:01 PM
$CLRB they have promising data. And he mentioned ongoing discussions for partnerships. ...
0 · Reply
bananastand1203
bananastand1203 Jan. 13 at 10:00 PM
$CLRB So I got from it that they’d be announce partnership soon since they said ideally before initiation of confirmation study for WM, which is slated for Q1 2026
1 · Reply
Aawilliam2003
Aawilliam2003 Jan. 13 at 9:58 PM
$CLRB public break out room #1
1 · Reply
Aawilliam2003
Aawilliam2003 Jan. 13 at 9:51 PM
$CLRB Jim are you really still talking about multiple myeloma? Good lord just sell the damn company
0 · Reply
Slab6
Slab6 Jan. 13 at 9:50 PM
$CLRB someone is underwater
0 · Reply
Aawilliam2003
Aawilliam2003 Jan. 13 at 9:41 PM
$CLRB and by the way, nobody gives a rats ass about Europe
2 · Reply